Karolinska Institute, Department of Clinical Neuroscience, Section of Psychiatry at Karolinska, University Hospital Huddinge, SE-141 86 Stockholm, Sweden.
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1117-21. doi: 10.1016/j.pnpbp.2011.03.012. Epub 2011 Mar 30.
Excessive level of radicals and/or dysfunctional antioxidant response, oxidative stress, is implicated in the pathogenesis of schizophrenia. A condition of oxidative stress has been detected in the brain, peripheral tissues and fluids including plasma. Plasma thioredoxin-1 (Trx1) is well characterized and a putative marker for oxidative stress and recently shown to be increased in plasma at the onset of schizophrenia. The present study aimed to explore whether Trx1 can be used as a marker to identify schizophrenic patients at the time-point when patients have their first episode of psychosis as compared to patients with long-term schizophrenia and mentally healthy patients, respectively. Plasma samples obtained from 18 patients at first episode of psychosis, from 49 long-term schizophrenic patients and from 20 mentally healthy controls (admitted with minor physical injury to the general ward) where analyzed by ELISA for Trx1. The patients with first episode of psychosis were diagnosed at least 6 months later and shown to constitute various psychotic syndromes, including schizophrenia, or affective disorder. The concentration of Trx1 in the patients with first episode of psychosis was 1.5 ± 1.0 ng/ml and 0.8 ± 0.6 ng/ml in controls. In the long-term schizophrenic patients the plasma concentration was 1.5 ± 0.7. The differences between the groups of acute psychotic or long-term schizophrenia patients to controls were significant (p < 0.016 and p < 0.001, respectively). Our data indicate that Trx1 may not be used as an early marker to identify schizophrenic patients in a mixed population of first episode psychotic patients. Further, Trx1 did not discriminate with reliable accuracy patients with psychotic disorder from mentally healthy controls on an individual basis due to overlap in levels of Trx1. However, our observations show that psychotic patients in general are in a significant long-term condition of oxidative stress, with possible implications for the profound morbidity and mortality found in this patient population.
自由基水平过高和/或抗氧化反应功能失调,即氧化应激,与精神分裂症的发病机制有关。氧化应激状态已在大脑、外周组织和体液(包括血浆)中检测到。血浆硫氧还蛋白-1(Trx1)的特征已得到充分描述,是氧化应激的一个潜在标志物,最近有研究表明,精神分裂症发病时,血浆 Trx1 水平升高。本研究旨在探讨 Trx1 是否可作为标志物,用于识别首发精神病患者,与长期精神分裂症患者和健康人群相比,分别在首发精神病患者发病时、长期精神分裂症患者和健康人群中进行检测。采用 ELISA 法检测 18 例首发精神病患者、49 例长期精神分裂症患者和 20 例健康对照者(因一般病房的轻微身体损伤而入院)的血浆 Trx1。首发精神病患者至少在 6 个月后被诊断为各种精神病综合征,包括精神分裂症或情感障碍。首发精神病患者的 Trx1 浓度为 1.5±1.0ng/ml,对照组为 0.8±0.6ng/ml。长期精神分裂症患者的血浆浓度为 1.5±0.7ng/ml。急性精神病患者或长期精神分裂症患者与对照组之间的差异具有统计学意义(p<0.016 和 p<0.001)。我们的数据表明,Trx1 可能不能作为识别混合首发精神病患者中精神分裂症患者的早期标志物。此外,由于 Trx1 水平的重叠,Trx1 不能可靠地准确区分精神病患者和健康对照者。然而,我们的观察结果表明,一般来说精神病患者处于长期的氧化应激状态,这可能对该患者群体中发现的高发病率和死亡率有影响。